View More Recent Stories
-
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
-
Goldman Sachs Reiterates Neutral Rating on Cytokinetics (CYTK)
-
Cytokinetics (CYTK) Announces Data From Phase 1 Study of CK-4021586
-
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
-
BofA Securities Reiterates Neutral Rating on Cytokinetics (CYTK)
-
Here's the list of biotech stocks that have key data catalysts in 2025
-
Cytokinetics (CYTK) PT Raised to $71 at JPMorgan
-
Mizuho Reiterates Outperform Rating on Cytokinetics (CYTK)
-
Goldman Sachs Reiterates Neutral Rating on Cytokinetics (CYTK)
-
Cytokinetics (CYTK) PT Raised to $92 at Jefferies
-
Goldman Sachs Downgrades Cytokinetics (CYTK) to Neutral
-
Eight defensive growth stocks to own right now
-
RBC's biotech survey shows investors more bearish vs. last time
-
Cytokinetics (CYTK) Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants
-
Piper Sandler Reiterates Overweight Rating on Cytokinetics (CYTK)

